TFF Pharmaceuticals’ (TFFP) “Buy” Rating Reaffirmed at HC Wainwright

TFF Pharmaceuticals (NASDAQ:TFFP – Get Rating)‘s stock had its “buy” rating restated by analysts at HC Wainwright in a research report issued on Friday, Benzinga reports. They presently have a $22.00 target price on the stock.

TFF Pharmaceuticals Stock Performance

NASDAQ TFFP opened at $0.74 on Friday. The firm has a market capitalization of $25.88 million, a PE ratio of -0.55 and a beta of 1.21. The company has a 50-day simple moving average of $0.89 and a 200-day simple moving average of $2.01. TFF Pharmaceuticals has a one year low of $0.62 and a one year high of $7.70.

Insider Activity at TFF Pharmaceuticals

In other news, CEO Harlan F. Weisman acquired 150,000 shares of the business’s stock in a transaction that occurred on Friday, March 10th. The shares were purchased at an average cost of $0.88 per share, for a total transaction of $132,000.00. Following the transaction, the chief executive officer now directly owns 214,615 shares in the company, valued at approximately $188,861.20. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders have bought a total of 177,000 shares of company stock worth $153,780 in the last ninety days. 4.60% of the stock is owned by insiders.

Institutional Trading of TFF Pharmaceuticals

A number of hedge funds and other institutional investors have recently made changes to their positions in TFFP. Two Sigma Investments LP bought a new stake in shares of TFF Pharmaceuticals during the 4th quarter worth about $60,000. Quantum Private Wealth LLC bought a new stake in shares of TFF Pharmaceuticals during the 2nd quarter worth about $62,000. Renaissance Technologies LLC bought a new stake in shares of TFF Pharmaceuticals during the 4th quarter worth about $76,000. Virtu Financial LLC bought a new stake in shares of TFF Pharmaceuticals during the 3rd quarter worth about $84,000. Finally, Sigma Planning Corp raised its position in shares of TFF Pharmaceuticals by 31.2% during the 4th quarter. Sigma Planning Corp now owns 100,891 shares of the company’s stock worth $106,000 after buying an additional 24,000 shares in the last quarter. 16.46% of the stock is currently owned by institutional investors.

About TFF Pharmaceuticals

(Get Rating)

TFF Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on developing and commercializing drug products based on its patented Thin Film Freezing (TFF) technology platform in the United States and Australia. It intends to focus on the development of inhaled dry powder drugs for the treatment of pulmonary diseases and conditions.